Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Revenue (2021 - 2024)

Amylyx Pharmaceuticals (AMLX) has 4 years of Revenue data on record, last reported at -$26.9 million in Q4 2024.

  • For Q4 2024, Revenue fell 124.77% year-over-year to -$26.9 million; the TTM value through Sep 2025 reached -$26.9 million, down 113.53%, while the annual FY2024 figure was $87.4 million, 77.05% down from the prior year.
  • Revenue reached -$26.9 million in Q4 2024 per AMLX's latest filing, down from $416000.0 in the prior quarter.
  • Across five years, Revenue topped out at $108.4 million in Q4 2023 and bottomed at -$26.9 million in Q4 2024.
  • Average Revenue over 4 years is $42.4 million, with a median of $21.9 million recorded in 2022.
  • Peak YoY movement for Revenue: skyrocketed 16274.41% in 2023, then plummeted 124.77% in 2024.
  • A 4-year view of Revenue shows it stood at $285000.0 in 2021, then soared by 7578.95% to $21.9 million in 2022, then soared by 395.54% to $108.4 million in 2023, then plummeted by 124.77% to -$26.9 million in 2024.
  • Per Business Quant database, its latest 3 readings for Revenue were -$26.9 million in Q4 2024, $416000.0 in Q3 2024, and $1.0 million in Q2 2024.